Optimising Treatment of HF
Published: 21 April 2021
3m 2sPart 1 PART 1 – Introduction – Optimising Treatment of HF Martin R Cowie
Following recent changes to guidelines in light of the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes, this programme brings together a leading faculty to best inform of the latest clinical evidence and real-world application for optimising treatment strategies in heart failure.
Prof Martin Cowie (Imperial College London, UK), moderates the proceedings, that comprises a number of insightful presentations and a panel discussion, with contributions from Prof Giuseppe Rosano (St George's Hospitals NHS Trust, London, UK), Dr Javed Butler (University of Mississippi, US), and Dr Shelley Zieroth (University of Manitoba, Canada).
- Recall recent changes to guidelines following the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes
- Describe the type and extent of clinical benefit observed when SGLT2 inhibitors are added to standard HF therapy in patients with HFrEF
- Assimilate prevailing hypotheses and insights from key thought leaders on optimal therapeutic sequencing of the ‘five pillars’ of HF therapy
- Apply newly gained knowledge on therapeutic sequencing to surrogate patient cases
- Heart Failure Specialists
- General Cardiologists
- Allied Health Professionals
More from this programme
PART 1 – Introduction – Optimising Treatment of HF
PART 2 – A Review of Recent SGLT2 Inhibitor Data
PART 3 – New HFrEF: When and How Should We Initiate an SGLT2 Inhibitor?
PART 4 – Existing HF-REF: Augmenting the SOC
PART 5 – How Will SGLT2 Inhibition Provide the Greatest Impact on HF-REF?
Consultant Cardiologist and Professor of Cardiology (Hon)
Giuseppe Rosano is Consultant Cardiologist and Professor of Cardiology at St George’s, University of London, UK where he is also the director of MSc Heart Failure.
His research interests focus on experimental and clinical pharmacology, heart failure, cardiac metabolism, diabetes and gender differences in cardiovascular diseases. Prof Rosano has been core member of the Cardiovascular Working Party of the European Medicines Agency and member of the Pricing and Reimbursement Committee of the Italian Drug Agency. He is the President-Elect of the Heart Failure Association Board (HFA), and Chairman of the Education Committee of the HFA. Prof Rosano is on the editorial board for European Journal of Heart Failure, European Heart Journal CV Pharmacotherapy, Cardiac Failure Reviews and Cardiovascular Diabetology. He has authored more than 500 peer…